Cargando…

Drotrecogin alfa (activated): down and not out, but not really in either

Detalles Bibliográficos
Autores principales:	Friedrich, Jan O, Adhikari, Neill KJ, Meade, Maureen O
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1751078/ https://www.ncbi.nlm.nih.gov/pubmed/17029652 http://dx.doi.org/10.1186/cc5022

Ejemplares similares

Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death
por: Friedrich, Jan O, et al.
Publicado: (2006)

Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?
por: Friedrich, Jan O, et al.
Publicado: (2006)

Timing of drotrecogin alfa (activated) treatment in severe sepsis
por: Choi, Goda, et al.
Publicado: (2006)

The safety profile of drotrecogin alfa (activated)
por: Fumagalli, Roberto, et al.
Publicado: (2007)

Practical aspects of treatment with drotrecogin alfa (activated)
por: Camporota, Luigi, et al.
Publicado: (2007)

Introduction: severe sepsis and drotrecogin alfa (activated)
por: Artigas, Antonio, et al.
Publicado: (2007)

Increasing microcirculation after drotrecogin alfa (activated)
por: Donati, A, et al.
Publicado: (2007)

Retrospective observational outcomes for drotrecogin alfa (activated)
por: Cameron, C, et al.
Publicado: (2007)

Drotrecogin alfa (activated) does not impair platelet receptor expression in vitro
por: Schuerholz, T, et al.
Publicado: (2004)

Clinical trials in severe sepsis with drotrecogin alfa (activated)
por: Laterre, Pierre-François
Publicado: (2007)

Use of national guidelines for the introduction of Drotrecogin alfa (activated)
por: Mackenzie, S, et al.
Publicado: (2004)

Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
por: Dhainaut, J, et al.
Publicado: (2008)

Drotrecogin alfa (activated): real-life use and outcomes for the UK
por: Rowan, Kathryn M, et al.
Publicado: (2008)

Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death
por: Williams, Mark D, et al.
Publicado: (2006)

Drotrecogin alfa (activated): a single-centre experience of 110 patients
por: Fletcher, S, et al.
Publicado: (2010)

Drotrecogin alfa: start early, ensure response, stop early!
por: Jog, S, et al.
Publicado: (2008)

Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis
por: Jamdar, Saurabh, et al.
Publicado: (2005)

Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
por: Levy, Howard, et al.
Publicado: (2005)

Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis
por: de Pont, Anne CJM, et al.
Publicado: (2009)

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
por: Bernard, Gordon R, et al.
Publicado: (2003)

Multicentre audit of the use of drotrecogin alfa (activated) in UK critical care units
por: Rowan, K, et al.
Publicado: (2007)

A large, single-centre UK registry of drotrecogin alfa-activated use
por: Macchiavello, L, et al.
Publicado: (2007)

Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry
por: Beale, R, et al.
Publicado: (2007)

The Use of Drotrecogin Alfa (activated) in a Patient With Severe Acute Respiratory Syndrom
por: Farooq, Warda, et al.
Publicado: (2003)

Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death
por: Gupta, Sanjay, et al.
Publicado: (2006)

Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
por: Sadique, M Zia, et al.
Publicado: (2011)

Drotrecogin alfa (activated) ... a sad final fizzle to a roller-coaster party
por: Angus, Derek C
Publicado: (2012)

Audit of adherence to National Institute of Clinical Excellence guidelines for the use of drotrecogin alfa (activated)
por: Vedantham, R, et al.
Publicado: (2007)

Neuroaxial catheters following abdominal surgery and their impact on the use of Drotrecogin alfa (activated) in sepsis
por: Steel, A, et al.
Publicado: (2004)

New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated)
por: Macias, William L, et al.
Publicado: (2005)

Does intensive insulin therapy really reduce mortality in critically ill surgical patients? A reanalysis of meta-analytic data
por: Friedrich, Jan O, et al.
Publicado: (2010)

Eligibility for drotrecogin alfa therapy on the basis of APACHE II score and organ failure
por: Shulman, R, et al.
Publicado: (2005)

Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis
por: Annane, Djillali, et al.
Publicado: (2018)

Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
por: Costa, Vania, et al.
Publicado: (2007)

Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock
por: Spapen, Herbert, et al.
Publicado: (2010)

The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
por: Martin, Greg, et al.
Publicado: (2009)

Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis in hospitalised patients
por: Launois, R, et al.
Publicado: (2002)

Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
por: Vincent, Jean-Louis, et al.
Publicado: (2006)

Testing of anti-activated protein C antibodies in four drotrecogin alfa (activated) severe sepsis studies
por: Yan, S, et al.
Publicado: (2008)

Gene array transcript profiling of human endothelial cells identifies pathways regulated by Drotrecogin alfa (activated)
por: Brueckmann, M, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_e82lubdt22ndo32r5cj26c36bc